SSgA Funds Management, Inc. recently announced the acquisition of new stake in Novavax, Inc. (NASDAQ:NVAX). The institutional investor has increased its shareholding in the Healthcare company by 43.32% to 14.58 million shares with purchase of 4.41 million shares. This fresh investment now brings its stake to 12.28% valued currently at $70.0 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.99 million to 11.32 million shares. And Shah Capital Management, Inc. has lifted its position by 15.51% or 0.85 million shares – to 6.33 million shares.
Currently, there are 118.79M common shares owned by the public and among those 111.93M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 32 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 72,911 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 20,087 shares.
The top 3 mutual fund holders in Novavax, Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund. SPDR S&P Biotech ETF owns 14.3 million shares of the company’s stock, all valued at over $68.64 million. The company sold -0.14 million shares recently to bring their total holdings to about 12.04% of the shares outstanding. Vanguard Total Stock Market ETF bought 0.97 million shares to see its total holdings expand to 3.82 million shares valued at over $18.32 million and representing 3.21% of the shares outstanding. Vanguard Small Cap Index Fund bought 0.56 million shares to bring its total holdings to over 2.87 million shares at a value of $13.79 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.42% of the shares outstanding.
However, the script later moved the day high at 4.1950, up 3.20%. The company’s stock has a 5-day price change of 0.24% and -34.74% over the past three months. NVAX shares are trading -12.71% year to date (YTD), with the 12-month market performance down to -61.84% lower. It has a 12-month low price of $3.98 and touched a high of $12.50 over the same period. NVAX has an average intraday trading volume of 7.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -8.00%, -18.02%, and -40.57% respectively.
Institutional ownership of Novavax, Inc. (NASDAQ: NVAX) shares accounts for 56.69% of the company’s 118.79M shares outstanding. Mutual fund holders own 21.71%, while other institutional holders and individual stakeholders account for 35.33% and 0.29% respectively.
It has a market capitalization of $497.73M and a beta (3y monthly) value of 1.45. The earnings-per-share (ttm) stands at -$6.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.70% over the week and 5.63% over the month.
Analysts forecast that Novavax, Inc. (NVAX) will achieve an EPS of -$0.38 for the current quarter, -$0.34 for the next quarter and -$0.72 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.29 while analysts give the company a high EPS estimate of $0.24. Comparatively, EPS for the current quarter was -$2.28 a year ago. Earnings per share for the fiscal year are expected to increase by 56.61%, and 78.19% over the next financial year.
Looking at the support for the NVAX, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on August 09, 2023, with the firm’s price target at $15.
